Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
Cancer Research and Treatment. 2022;54(1):140-149 
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Trends in Cancer. 2019;5(11):677-692
P8‐21: Heterogeneity among tumors with acquired resistance to EGFR‐TKIs harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
Respirology. 2021;26(S3):295-295
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs
Lung Cancer. 2018;118:173-175
ID3021 Acquired resistance to with EGFR tyrosine kinase inhibitors by the EGFR T790M mutation in non-small cell lung cancer
Biomedical Research and Therapy. 2017;4(S):33
Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Cancers. 2019;11(7):923
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
Lung Cancer. 2014;83(1):44-50
Long Non-Coding Rna Uca1 Induces Acquired Resistance of Egfr-Tkis in Non-Small Cell Lung Cancer
Annals of Oncology. 2014;25:iv64
Apatinib with first-generation EGFR-TKIs as second-line treatment for patients with advanced non-small cell lung cancer with acquired resistance: a retrospective case series analysis
. 2023;
Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signalling in non-small cell lung cancer without harboring EGFR T790M mutation
. 2020;